115 related articles for article (PubMed ID: 15737694)
1. Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development.
Zirn B; Wittmann S; Graf N; Gessler M
Cancer Lett; 2005 Mar; 220(1):115-20. PubMed ID: 15737694
[TBL] [Abstract][Full Text] [Related]
2. Is the gene encoding Chibby implicated as a tumour suppressor in colorectal cancer ?
Gad S; Teboul D; Lièvre A; Goasguen N; Berger A; Beaune P; Laurent-Puig P
BMC Cancer; 2004 Jul; 4():31. PubMed ID: 15245581
[TBL] [Abstract][Full Text] [Related]
3. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
4. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
5. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
6. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
7. Axin, the main component of the Wnt signaling pathway, is not mutated in kidney tumors in children.
Miao J; Kusafuka T; Udatsu Y; Okada A
Int J Mol Med; 2002 Apr; 9(4):377-9. PubMed ID: 11891531
[TBL] [Abstract][Full Text] [Related]
8. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
9. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
10. CTNNB1 (beta-catenin) mutation is rare in brain tumours but involved as a sporadic event in a brain metastasis.
Lee CI; Hsu MY; Chou CH; Wang C; Lo YS; Loh JK; Howng SL; Hong YR
Acta Neurochir (Wien); 2009 Sep; 151(9):1107-11. PubMed ID: 19582367
[TBL] [Abstract][Full Text] [Related]
11. The Wnt-signaling pathway is not implicated in tumorigenesis of Merkel cell carcinoma.
Liu S; Daa T; Kashima K; Kondoh Y; Yokoyama S
J Cutan Pathol; 2007 Jan; 34(1):22-6. PubMed ID: 17214850
[TBL] [Abstract][Full Text] [Related]
12. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.
Groen RW; Oud ME; Schilder-Tol EJ; Overdijk MB; ten Berge D; Nusse R; Spaargaren M; Pals ST
Cancer Res; 2008 Sep; 68(17):6969-77. PubMed ID: 18757411
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of Wnt signaling molecules in ameloblastoma with aberrant nuclear expression of beta-catenin.
Tanahashi J; Daa T; Yada N; Kashima K; Kondoh Y; Yokoyama S
J Oral Pathol Med; 2008 Oct; 37(9):565-70. PubMed ID: 18284543
[TBL] [Abstract][Full Text] [Related]
14. Dominant-stable beta-catenin expression causes cell fate alterations and Wnt signaling antagonist expression in a murine granulosa cell tumor model.
Boerboom D; White LD; Dalle S; Courty J; Richards JS
Cancer Res; 2006 Feb; 66(4):1964-73. PubMed ID: 16488995
[TBL] [Abstract][Full Text] [Related]
15. Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.
Jilong Y; Jian W; Xiaoyan Z; Xiaoqiu L; Xiongzeng Z
Pathology; 2007 Jun; 39(3):319-25. PubMed ID: 17558858
[TBL] [Abstract][Full Text] [Related]
16. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
17. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of beta-catenin inhibitor Chibby in colon carcinoma cell lines.
Schuierer MM; Graf E; Takemaru K; Dietmaier W; Bosserhoff AK
World J Gastroenterol; 2006 Mar; 12(10):1529-35. PubMed ID: 16570344
[TBL] [Abstract][Full Text] [Related]
19. beta-Catenin mutation and its nuclear localization are confirmed to be frequent causes of Wnt signaling pathway activation in pilomatricomas.
Xia J; Urabe K; Moroi Y; Koga T; Duan H; Li Y; Furue M
J Dermatol Sci; 2006 Jan; 41(1):67-75. PubMed ID: 16378715
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
